Date: 2012-10-31
Type of information: Fundraising
Company: Phenex Pharmaceuticals (Germany)
Investors: EVP Capital Partners (Germany)
Amount: € 5 million
Funding type:
Planned used: The additional funds will be earmarked for the further development of Px-102 and to broaden the ongoing RORgamma-T program.
Others: Phenex Pharmaceuticals has concluded a fourth round of funding. Recent data on Px-102 together with the progress in a second R&D program which targets RORgamma-T prompted Phenex existing investors to invest another € 5 million into Phenex.
Therapeutic area: Autoimmune diseases – Immunological diseases - Liver diseases
